Skip to main content
. 2022 Nov 19;13(1):221–234. doi: 10.1007/s13555-022-00842-7

Fig. 2.

Fig. 2

Patients achieving EASI 75 and EASI 90 from baseline to week 112. Data are presented using the observed cases approach. All patients received concomitant topical corticosteroids from baseline to week 16. After week 16, the use of concomitant topical corticosteroids was no longer required and was administered per investigator discretion. EASI 75/90 ≥ 75%/ ≥ 90% improvement in Eczema Area Severity Index, PBO placebo, UPA upadacitinib